NTLAIntellia Therapeutics, Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is NTLA?
Intellia Therapeutics, Inc. keeps −712% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- +29%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 583%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −236% |
| FY2021 | −810% |
| FY2022 | −879% |
| FY2023 | −1421% |
| FY2024 | −923% |
| FY2025 | −652% |
Details›
- Operating margin12 months to Q2 2026
- −712%
- Net margin12 months to Q2 2026
- −672%
- Free cash flow margin
- −586%
- R&D as % of revenue
- 583%
- Revenue, trailing twelve months
- $60M
- Free cash flow, trailing twelve months
- −$349M
- Net income, trailing twelve months
- −$400M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.